SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC: San Diego Saturday, January 3, 2026, 18:00 H ...
The ROR family of proteins includes ROR1 and ROR2 – receptor tyrosine kinases. ROR1 is especially interesting to pharmacologists as it has only been observed in cancerous and embryonic cells, and ...
The False Son is a unique Risk of Rain 2 character who makes frequent use of both melee and ranged attacks. He can be a little confusing to use at first, but once players get the groove of his ...
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination ...
The mechanism underlying astrocyte-mediated restoration of brain tissue after an injury has now been pinpointed by a team of researchers. This could lead to new treatments that encourage regeneration ...
BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction. BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback